Statements (60)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
clinical trial
|
| gptkbp:analyzes |
multiple hospitals
venetoclax intention-to-treat |
| gptkbp:built |
2018
|
| gptkbp:clinicalTrials |
yes
high two Phase III obtained NCT02005471 |
| gptkbp:collaborations |
gptkb:Roche
|
| gptkbp:collection |
clinical assessments
|
| gptkbp:contraindication |
reported side effects
|
| gptkbp:controls |
bendamustine_plus_rituximab
|
| gptkbp:courseRating |
multicenter
|
| gptkbp:dataUsage |
yes
available upon request |
| gptkbp:distribution |
yes
|
| gptkbp:enrollment |
389 participants
|
| gptkbp:focusesOn |
chronic lymphocytic leukemia
|
| gptkbp:followedBy |
24 months
|
| gptkbp:funding |
pharmaceutical industry
|
| gptkbp:future_plans |
Phase 3
|
| gptkbp:hasPopulation |
relapsed_or_refractory_CLL
|
| gptkbp:healthcare |
diverse population
completed successfully |
| gptkbp:historicalResearch |
long-term effects of treatment
|
| https://www.w3.org/2000/01/rdf-schema#label |
MURANO trial
|
| gptkbp:impact |
influenced treatment protocols
|
| gptkbp:includes |
previous treatment with BCL-2 inhibitors
adults_with_CLL |
| gptkbp:is_studied_in |
yes
positive completed highly regarded in the field short follow-up period significant improvement in PFS |
| gptkbp:isPublishedIn |
gptkb:The_New_England_Journal_of_Medicine
|
| gptkbp:launchDate |
2014
|
| gptkbp:leads |
gptkb:Dr._John_C._Byrd
|
| gptkbp:location |
multiple countries
|
| gptkbp:moral |
yes
|
| gptkbp:outcome |
safety and efficacy
|
| gptkbp:primaryMission |
treatment
progression-free survival |
| gptkbp:regulatoryCompliance |
supported by trial results
|
| gptkbp:relatedModel |
parallel assignment
|
| gptkbp:relatedTo |
bendamustine_plus_rituximab
venetoclax_plus_rituximab |
| gptkbp:releaseYear |
2019
|
| gptkbp:research |
venetoclax
provided_by_AbbVie |
| gptkbp:research_areas |
hematology
|
| gptkbp:researchField |
oncology
|
| gptkbp:researchInterest |
adhered to guidelines
|
| gptkbp:result |
venetoclax plus rituximab improved outcomes
|
| gptkbp:secondaryMission |
overall survival
|
| gptkbp:sponsor |
AbbVie
|
| gptkbp:vision |
no
|